CARDIFF ONCOLOGY INC CRDF
ASignal's systematic analysis rates CRDF as Bearish.
Reflects the latest available analysis · analyzed Oct 30, 2026
The case on CRDF
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong financial health score (0.9)
- Low debt-to-equity ratio (0.02x)
- High cash reserves ($34.52M) relative to market cap
- Current ratio (3.30x) indicates solid short-term liquidity
- MACD below signal line with negative histogram
- Negative price momentum trend
- Extremely poor operating margin (-9245.19%)
- Negative return on equity (-94.08%) and return on assets (-46.73%)
- Negative free cash flow (-$24.30M)
- High EV/Revenue (72.61x) and Price/Sales (136.23x) for a declining revenue company
See the full verdict on CRDF
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes CRDF
Most investors never get a second opinion, let alone several. ASignal runs CRDF past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.